Events, Marketing Recommendation, FDA Meeting, and Marketing Authorization - Research Report on Hospira, Novo Nordisk, Repros Therapeutics, GW Pharmaceuticals, and Envision Healthcare

NEW YORK, December 2, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Hospira Inc. (NYSE: HSP), Novo Nordisk A/S (NYSE: NVO), Repros Therapeutics Inc. (NASDAQ: RPRX), GW Pharmaceuticals plc (NASDAQ: GWPH), and Envision Healthcare Holdings, Inc. (NYSE: EVHC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Hospira Inc. Research Report

On November 26, 2013, Hospira Inc. (Hospira) announced that it will conduct an Investor Day at the Company's headquarters on Thursday, December 5, 2013, from 8:00 a.m. to 3:15 p.m. CT. According to the Company, F. Michael Ball, CEO, and several members of the senior management team at Hospira will host the aforesaid presentation. The Company notified that a live audio webcast of the presentation and a replay version of the same will be accessible through the Investor Relations website. The Full Research Report on Hospira Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/1f43_HSP

--

Novo Nordisk A/S Research Report

On November 22, 2013, Novo Nordisk A/S (Novo Nordisk) reported that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has issued a supportive note, recommending the marketing of NovoRapid PumpCart, a prefilled insulin pump cartridge, developed in a non-exclusive partnership between the Company and Roche Diabetes Care in Europe. Novo Nordisk reported that it expects to launch NovoRapid PumpCart in selected European countries during 2014 and 2015. Luc Vierstraete, Global Head of Roche Diabetes Care, said, "We are excited to be able to offer this solution to our customers and bring to market our innovative Accu-Chek® Insight diabetes therapy system compatible with the option of using the new prefilled insulin cartridge. This can help to enhance the advantages of a targeted and effective insulin pump therapy while contributing to a simplified diabetes management in everyday life." The Full Research Report on Novo Nordisk A/S - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/fee1_NVO

--

Repros Therapeutics Inc. Research Report  

On November 25, 2013, Repros Therapeutics Inc. (Repros) reported that it has been granted a face to face meeting with the US Food and Drug Administration (FDA) to discuss the pivotal Androxal efficacy studies (as directed by the FDA on October 22, 2013). Repros reported that the Agency will have had the final clinical study reports made available prior to the meeting, which will also address the unmet medical need for therapy producing restoration of total testicular function, i.e. restoration of T levels without the characteristic suppression of spermatogenesis by marketed testosterone replacement products. The Company informed that it has proposed the attendance of two Repros' key opinion leaders, Wayne Hellstrom, M.D., F.A.C.S., Professor of Urology and Chief of Andrology, Tulane University and incoming President of ISSM, and Edward Kim, Ph.D., Professor at University of Tennessee Graduate School of Medicine. Repros notified that it will issue an official press release about the outcome of the meeting before the end of February 2014. The Full Research Report on Repros Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/2334_RPRX

--

GW Pharmaceuticals plc Research Report

On November 27, 2013, GW Pharmaceuticals plc (GW Pharmaceuticals) announced that it has received a full marketing authorization for its prescription medicine Sativex® in Switzerland, from the Swissmedic authorities for the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications. The Company stated that Sativex will be commercialized in Switzerland by its European partner, Almirall S.A., and its launch timing is dependent on completion of pricing and reimbursement procedures. Justin Gover, CEO of GW Pharmaceuticals, said, "This approval in Switzerland marks yet another regulatory success for Sativex, which is now approved in a total of 23 countries." Gover added, "We now look forward to working with our partners, Almirall, towards this launch so as to enable MS patients in Switzerland to benefit from this important new treatment." The Full Research Report on GW Pharmaceuticals plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/26a5_GWPH

--

Envision Healthcare Holdings, Inc. Research Report

On November 25, 2013, Envision Healthcare Holdings, Inc. and Envision Healthcare Corporation (together Envision Healthcare) jointly announced that Bill Sanger, CEO, and Randy Owen, CFO/Chief Operating Officer, will represent the Company at two upcoming conferences in December 2013. According to the Company, Mr. Sanger and Mr. Owen is scheduled to speak at the Piper Jaffray Healthcare Conference in New York, on Wednesday, December 4, 2013 at 1:00 p.m. ET as well as at the Oppenheimer Healthcare Conference in New York, on Wednesday, December 11, 2013 at 10:05 a.m. ET. Envision Healthcare reported that a live audio webcasts and its replay version can be accessed by interested parties through its Investor Relations website. The Full Research Report on Envision Healthcare Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/73be_EXEL

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner